Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Ofran Y, Leiba R, Frisch A, Horesh N, Henig I, Yehudai-Ofir D, Moshe Y, Neaman M, Ganzel C, Gal-Rabinovich K, Hellmann I, Weinstein V, Berger T, Wolach O. Ofran Y, et al. Among authors: wolach o. Eur J Haematol. 2021 Jan;106(1):64-71. doi: 10.1111/ejh.13518. Epub 2020 Oct 6. Eur J Haematol. 2021. PMID: 32949053
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Kugler E, Cohen I, Amitai I, Ram R, Frisch A, Nachmias B, Canaani J, Moshe Y, Krayem B, Aumann S, Henig I, Vainstein V, Shargian L, Ganzel C, Yeshurun M, Levi I, Raanani P, Akria L, Ofran Y, Shimony S, Wolach O. Kugler E, et al. Among authors: wolach o. Br J Haematol. 2024 Sep;205(3):932-941. doi: 10.1111/bjh.19548. Epub 2024 May 23. Br J Haematol. 2024. PMID: 38782575
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A, Moshe Y, Ofran Y, Gural A, Wolach O, Ganzel C, Canaani J, Zektser M, Duek A, Stemer G, Hellman I, Basood M, Frisch A, Leibovitch C, Koren-Michowitz M. Apel A, et al. Among authors: wolach o. Am J Hematol. 2021 Jul 1;96(7):790-795. doi: 10.1002/ajh.26190. Epub 2021 Apr 29. Am J Hematol. 2021. PMID: 33836555 Free article.
Trial eligibility, treatment patterns and outcome for venetoclax-based therapy in AML: a prospective cohort study.
Wolach O, Levi I, Nachmias B, Tavor S, Amitai I, Ofran Y, Ganzel C, Zuckerman T, Okasha D, Hellmann I, Tadmor T, Dally N, Canaani J, Stemer G, Grunspan M, Berger AJ, Frankel N, Berelovich J, Bleterman A, Barak M, Cohen R, Moshe Y. Wolach O, et al. Blood Adv. 2024 Dec 5:bloodadvances.2024014014. doi: 10.1182/bloodadvances.2024014014. Online ahead of print. Blood Adv. 2024. PMID: 39637307
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
Berger T, Rozovski U, Moshe Y, Yaari S, Frisch A, Hellmann I, Apel A, Aviram A, Koren-Michowitz M, Yeshurun M, Ram R, Raanani P, Ofran Y, Wolach O. Berger T, et al. Among authors: wolach o. Ann Hematol. 2019 Dec;98(12):2711-2717. doi: 10.1007/s00277-019-03795-8. Epub 2019 Sep 11. Ann Hematol. 2019. PMID: 31512015 Clinical Trial.
Venetoclax is safe and efficacious in relapsed/refractory AML.
Ganzel C, Ram R, Gural A, Wolach O, Gino-Moor S, Vainstein V, Nachmias B, Apel A, Koren-Michowitz M, Pasvolsky O, Yerushalmi R, Danylesko I, Cohen Y, Peretz G, Moshe Y, Zektser M, Yeganeh S, Rowe JM, Ofran Y. Ganzel C, et al. Among authors: wolach o. Leuk Lymphoma. 2020 Sep;61(9):2221-2225. doi: 10.1080/10428194.2020.1761964. Epub 2020 May 18. Leuk Lymphoma. 2020. PMID: 32420775
90 results